Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05101122 · ClinicalTrials.gov registry record · Phase 1
Study for Efficacy and Dose Escalation of AD313 + Atomoxetine (SEED)
A Phase 1 study, sponsored by Apnimed.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT05101122 is a Phase 1 study that has completed, run by Apnimed. The registered enrollment target is 15 participants.
The verdict
NCT05101122, a Phase 1 study, has completed, sponsored by Apnimed.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The SEED study is designed to assess the safety and efficacy for Obstructive Sleep Apnea (OSA) of 3 escalating dose combinations of atomoxetine with AD313 compared to baseline and to atomoxetine alone.
Interventions
- DRUG Dosing 1: Atomoxetine
- DRUG AD313
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2021-10-19 |
| Est. Completion | 2022-04-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05101122
The ClinicalTrials.gov registry entry for NCT05101122 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Apnimed, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dosing 1: Atomoxetine is the first listed.
NCT05101122 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05101122 about?
NCT05101122 is a clinical study titled "Study for Efficacy and Dose Escalation of AD313 + Atomoxetine (SEED)". The SEED study is designed to assess the safety and efficacy for Obstructive Sleep Apnea (OSA) of 3 escalating dose combinations of atomoxetine with AD313 compared to baseline and to atomoxetine alone.
What is the current status of trial NCT05101122?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2021-10-19. Estimated completion is 2022-04-18.
What interventions are being tested in trial NCT05101122?
The interventions under investigation include: Dosing 1: Atomoxetine (DRUG), AD313 (DRUG).
Who is sponsoring clinical trial NCT05101122?
This trial is sponsored by Apnimed, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.